Climb Bio initiated with a Buy at BTIG

BTIG initiated coverage of Climb Bio (CLYM) with a Buy rating and $7 price target Climb’s budoprutug is only the second anti-CD19 monoclonal antibody that has been advanced into the clinic for immunology and inflammation development, says the analyst, who views “Uplizna 2.0” as well-positioned to thrive in a wide range of I&I opportunities. The firm expects budoprutug to emerge as the best-in-class mAb supported by a longer half-life, higher solubility, and higher affinity compared to Uplizna, the analyst tells investors.